A 50-year-old man, in apparently good health, was referred to the Lipid Center of San Luigi Gonzaga Hospital, Orbassano (Turin, Italy), by his primary care physician (PCP) because clinical tests at the time of blood donation showed milky plasma with serious hypertriglyceridaemia (\>5000 mg/dl) and hyperglycaemia (381 mg/dl), diagnostic for diabetes. It was not possible to perform further blood chemical analyses because hypertriglyceridaemia would have provided abnormal results. The patient entered the hospital to prevent acute pancreatitis, which is often associated with severe hypertriglyceridaemia.

The clinical history revealed *H. pylori*-associated gastric ulcer in the prior year. At that time, laboratory tests disclosed "mild" hyperglycaemia and hypertriglyceridaemia (the patient's records were misplaced.) An ill-defined hypolipidaemic diet was recommended at discharge, but the suggestion was neglected. He was a former smoker (30 pack year, stopping about 10 years before), and consumed a diet rich in saturated fats and carbohydrates while alcohol ingestion was mild and occasional (2--3 drinks per week). His living mother was affected by type 2 diabetes; his father died by accident at a young age, while a brother suffered a myocardial infarction at age 43, seemingly not related to traditional cardiovascular risk factors. The patient weighed 79 kg and was 1.75 m tall (Body Mass Index, BMI=25.8 kg/m^2^), and there had been no significant recent weight modification. No significant abnormalities were detected at physical examination.

Biochemical analyses (Table [1](#Tab1){ref-type="table"}) corroborated the findings of severe hypertriglyceridaemia (6.594 mg/dl), showing also high cholesterol levels (658 mg/dl) and low plasma high-density lipoprotein cholesterol (HDL-C, 15 mg/dl); apolipoprotein A-I was 75 mg/dl and apolipoprotein B was 141 mg/dl, both within normal laboratory range. After refrigeration overnight at +4°C, serum showed a creamy surface layer and a turbid infranatant, while lipoprotein electrophoresis disclosed lipids at origin and a broad pre-β band: both these tests indicated the presence of chylomicrons and very low-density lipoproteins (VLDLs). Plasma creatinine was within normal limits, while urinalysis detected trace amounts of glucose and ketone bodies; liver and thyroid functions were also normal; γ-glutamyl-transferase was slightly increased and serum sodium decreased. Glucose level (215 mg/dl) and glycated haemoglobin (HbA1c) were increased, C-peptide was in the normal-high range, while immune parameters were unaffected, in particular anti-islet cells antibodies (ICA) and glutamic acid decarboxylase antibodies (GADA) were not detected. Table 1Biochemical tests after hospital admissionCholesterol658 mg/dlAnti-insula AbNegativeUric acid5.8 mg/dlTriglycerides6594 mg/dlAnti-GAD AbNegativeTotal proteins7.8 g/dlHDL-chol15 mg/dlLeucocytes4290/mm3ALT26U/1Apo AI75 mg/dlHaemoglobin14.1 g/dlγ-Glutamyl-transferase112 U/lApo B141 mg/dlhs-CRP0.26 mg/dlBilirubin0.5 mg/dlFasting glycaemia215 mg/dlSodium133 mEq/1Amylase30 U/LGlycated haemoglobin10.5%Potassium4.5 mEq/1TSH2.2 μUI/mlC-peptide3.5 ng/mlCreatinine0.9 mg/dlf-Thyroxine1.2ng/dl

Preparative ultracentrifugation was carried out, showing cholesterol enrichment in the density fraction \<1.006 g/ml, corresponding to chylomicrons+VLDLs. Apolipoprotein E was homozygous for the most common isoform (ε3/ε3 genotype). We did not disclose a deficiency of apolipoprotein C-II, which represents the physiological lipoprotein lipase (LPL) activator, but we could not directly evaluate LPL activity.

Supra-aortic and lower limb echo-doppler examination revealed increased intima-media thickness but no plaques, while liver echotomography showed diffuse, high-grade steatosis.

Along with clinical evaluation, dietetic therapy and a four-injection insulin regimen was administered (3 short-acting pre-prandial insulin, and one bedtime long-acting dose). Treatment resulted in rapidly improving and rather steady glycaemic control with progressive reduction of insulin requirement. At the same time the dyslipidaemia was treated with low-fat diet, subcutaneous calcium heparin (2000 IU, bid), fenofibrate (200 mg, qd) and omega-3 fatty acids (1 g, tid). Plasma triglycerides decreased in a few days, followed by blood cholesterol (Fig. [1](#Fig1){ref-type="fig"}). After lipid pattern improvement, insulin treatment was completely discontinued, and the patient was successfully treated with only diet and metformin; also subcutaneous heparin was stopped, while fibrates and polyenoic fatty acids were maintained. His weight decreased by 3--4 kg during the hospital stay, while 6 months afterwards his BMI was 25.2 kg/m^2^. Fig. 1Lipoprotein parameters during hospital stay and after discharge

In short, we report a case of a patient with massive dyslipidaemia associated with glycaemic decompensation, in the framework of previously unrecognised type 2 diabetes, anamnestic hints of "slight", not further defined, hyperglycaemia and a familial history of diabetes. Increased HbA1c plasma levels suggest that diabetic decompensation occurred during weeks or months before, and not in a few days time, while high C-peptide plasma levels in the context of overt hyperglycaemia testify to a relative insulin deficiency and marked insulin resistance. Finally, the absence of immune markers rule out the presence of latent autoimmune diabetes in the adult (LADA), a peculiar form of smoldering type 1 diabetes that appears during adulthood. Dyslipidaemia is a common finding in diabetic populations, and represents a major coronary heart disease risk factor \[[@CR1]\]. It may be found when type 2 diabetes is diagnosed, persisting in spite of hypoglycaemic therapy and closely related to insulin-resistance parameters. It is generally characterised by moderate hypertriglyceridaemia and low HDL-C plasma levels, while total and low-density lipoprotein-cholesterol (LDL-C) concentrations are similar to non-diabetic subjects; however LDL particles are smaller and denser than usual, and possibly more atherogenic. Moreover, the LDLs and HDLs are triglyceride- enriched \[[@CR2], [@CR3]\]. Less frequently, diabetes begins with a chylomicronemic syndrome. In our patient, hyperlipidaemia was at first characterised by very high triglycerides and cholesterol plasma levels. Blood triglycerides exceeding 2000 mg/dl are a rare clinical finding; when such values are present, several haematochemical parameters may look abnormal as a result of analytical interference or uneven analyte distribution (the "false" hyponatraemia we found is ascribable to the presence of sodium only in the watery plasma phase, while the lipid phase, about 10% of total plasma volume, is not permeable to sodium).

The most common primary causes of severe hypertriglyceridaemia are familial LPL deficiency and familial apo C-II deficiency (the physiological LPL activator), which may account for up to 10% of all individuals referred to a lipid clinic with the chylomicronaemia syndrome \[[@CR4]\]. The transient hypertriglyceridaemia of our patient was not in agreement with familial conditions, characterised by rather steadily increased lipid values (also above 5--10 000 mg/dl), and not responsive to drug treatment. The coexistence of high plasma cholesterol and triglycerides with fasting chylomicrons may suggest type III hyperlipidaemia. This lipid disorder (also known as 'dysbetalipoproteinaemia' or 'broad-beta disease') is a rare condition (1:10 000 subjects) and much more frequent in subjects with an uncommon apolipoprotein E genotype (ε2/ε2). It is characterised by the development of premature atherosclerosis and plasma accumulation of partially catabolised chylomicrons and VLDLs \[[@CR5]\]. Dyslipidaemic patients show increased cholesterol and triglyceride levels (\>300 mg/dl) and a peculiar "broad beta" band between β (LDL) and pre-β (VLDL) bands at lipoprotein electrophoresis; chylomicrons may be present in variable amounts. In this case, however, a very distinct electrophoretic β-band and a common apolipoprotein ε3/ε3 genotype rule out the hypothesis of type III hyperlipoproteinaemia.

Another rare hyperchylomicronaemic syndrome (with a prevalence of about 1:10 000 in the general population) is Fredrickson type V dyslipidaemia. In this condition both VLDL and chylomicron levels are increased, while plasma triglycerides are very high. It may display either a primary or a secondary origin: in the latter case obesity, pregnancy, ethanol intake, estro-progestins, β-blockers or anion exchange resins, hypothyroidism, kidney disease and diabetes may favour its appearance in predisposed individuals. Our patient seems classifiable in this type of dyslipidaemia. Likely some concurrent lipid metabolism abnormality (e.g., familial combined hyperlipidaemia or heterozygous LPL deficiency) may represent the fuel promoting hyperchylomicronaemia (+VLDLs) in response to hyperglycaemic decompensation, most probably feed-back by incoming hypertriglyceridaemia as part of a well known vicious cycle \[[@CR6], [@CR7]\]. This fact might explain both transient type IIb hyperlipidaemia during clinical type V remission, and the familial history of coronary heart disease. His lipid profile 6 months after hospital discharge was alternatively normal, or suggestive of type IV hyperlipaemia. Our diagnosis is probable but the pathophysiology is presumptive, as important data are lacking (LPL activity or gene sequencing); however therapy response and patient followup add reliability to this interpretation.

Interestingly our patient was substantially asymptomatic: clinical complications of hyperchylomicronaemia (acute pancreatitis, eruptive xanthomatosis) are particularly common with plasma triglyceride levels above 2000 mg/dl \[[@CR4]\], but sometimes, unpredictably, they may be absent. The relationship between hyperchylomicronaemia and premature atherosclerosis is still controversial, denied by most authors, but has received some valuable confirmation \[[@CR8]\].

Treatment improved the lipid pattern after only a few days. A lipid-poor diet, in particular, represents the cornerstone of early treatment. Fibrates are then particularly indicated: after interacting with a specific nuclear receptor (peroxisome proliferator activated receptor-α, PPARα), they fasten LPL-induced lipolysis (especially by blocking apo C-III synthesis, a main lipoprotein lipase-inhibitor), and decrease liver triglycerides and apolipoprotein B secretion \[[@CR9]\]. Heparin was effective in the short term, but its role in severe hypertriglyceridaemia is still under discussion \[[@CR10]\]. It has been defined as a "plasma clearing factor" showing hypotriglyceridaemic effect in an acute setting, and may be useful when pancreatitis supervenes, especially in conjunction with insulin treatment \[[@CR10], [@CR11]\]. Heparin may release LPL from the endothelial surface of extrahepatic tissues, promoting its access to blood where the enzyme hydrolyses VLDL and chylomicron triglycerides. However, after a quick peak effect, chronic heparin infusion causes lipase activity to reach a plateau that is substantially lower than the former level (about 15%), decreasing correspondingly the tissue stores (likely by hepatic catabolism of circulating LPL molecules) \[[@CR12]\]. This makes its long-term utilisation particularly questionable. Omega-3 fatty acids are another debated drug; they display hypotriglyceridaemic effect when administered to subjects with high VLDL plasma levels, while in type V patients there is no consensus on their efficacy (they could even be detrimental, favouring chylomicron synthesis in enterocytes). Also plasmapheresis may represent, in selected contexts, a useful but extreme therapeutical tool \[[@CR13]\].

Finally, insulin effect must not be underestimated: it is always advisable in diabetic patients when marked hypertriglyceridaemia is recognised. In fact insulin can stimulate LPL production, inhibit endogenous triglyceride synthesis and promote their catabolism \[[@CR14]\].
